Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P43631

UPID:
KI2S2_HUMAN

ALTERNATIVE NAMES:
CD158 antigen-like family member J; NK receptor 183 ActI; Natural killer-associated transcript 5; p58 natural killer cell receptor clone CL-49

ALTERNATIVE UPACC:
P43631; Q14955; Q6H2G9

BACKGROUND:
The protein Killer cell immunoglobulin-like receptor 2DS2, identified by the accession number P43631, is crucial for the interaction between natural killer (NK) cells and HLA-C alleles. It does not inhibit NK cell activity, thereby playing a significant role in immune surveillance. Its alternative names include Natural killer-associated transcript 5 and p58 natural killer cell receptor clone CL-49.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Killer cell immunoglobulin-like receptor 2DS2 offers a promising avenue for the development of novel immunotherapies. By modulating NK cell activity, it holds the potential to contribute to treatments targeting cancer and infectious diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.